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Background:  BCG  is  used  widely  as  the  sole  licensed  vaccine  against  tuberculosis,  but  it has  variable
efﬁcacy  and the  reasons  for  this  are  still unclear.  No  reliable  biomarkers  to  predict  future  protection
against,  or  acquisition  of,  TB infection  following  immunisation  have  been  identiﬁed.  Lessons  from  BCG
could  be  valuable  in  the  development  of effective  tuberculosis  vaccines.
Objectives:  Within  the  Entebbe  Mother  and  Baby  Study  birth  cohort  in Uganda,  infants  received  BCG
at  birth.  We  investigated  factors  associated  with  latent  tuberculosis  infection  (LTBI)  and with  cytokine
response  to mycobacterial  antigen  at age  ﬁve  years.  We  also  investigated  whether  cytokine  responses  at
one year  were  associated  with  LTBI at  ﬁve  years  of  age.
Methods:  Blood  samples  from  age  one  and  ﬁve  years  were  stimulated  using  crude  culture  ﬁltrates  of
Mycobacterium  tuberculosis  in a six-day  whole  blood  assay.  IFN-,  IL-5, IL-13  and  IL-10  production  was
measured.  LTBI  at ﬁve  years  was  determined  using  T-SPOT.TB® assay.  Associations  with  LTBI  at ﬁve  years
were  assessed  using  multivariable  logistic  regression.  Multiple  linear  regression  with  bootstrapping  was
used  to determine  factors  associated  with  cytokine  responses  at age ﬁve  years.
Results: LTBI  prevalence  was  9% at age  ﬁve  years.  Only  urban  residence  and  history  of  TB contact/disease
were  positively  associated  with  LTBI.  BCG  vaccine  strain,  LTBI,  HIV  infection,  asymptomatic  malaria,
growth  z-scores,  childhood  anthelminthic  treatment  and  maternal  BCG scar were  associated  with
cytokine  responses  at age  ﬁve.  Cytokine  responses  at one  year  were  not  associated  with acquisition
of  LTBI  by  ﬁve  years  of age.
Conclusion:  Although  multiple  factors  inﬂuenced  anti-myocbacterial  immune  responses  at  age  ﬁve,  fac-
tors likely  to be  associated  with  exposure  to infectious  cases  (history  of  household  contact,  and  urban
residence)  dominated  the risk  of LTBI.
© 2014  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Latent tuberculosis infection (LTBI) is an important reservoir
from which new tuberculosis (TB) cases arise. In children, active
TB disease results either from reactivation of LTBI or from pri-
mary infection acquired from contact with an infectious individual
[1]. Lifetime risk of LTBI reactivation is approximately 10% [2].
In endemic settings, Bacille Calmette–Guerin (BCG) is routinely
∗ Corresponding author. Tel.: +256 417 704000; fax: +256 414 321137.
E-mail addresses: swaiblule@gmail.com, swaiblule@yahoo.com (S.A. Lule).
offered to protect infants from TB [3]. Recently, evidence has
accrued that BCG may  protect against infection with Mycobacterium
tuberculosis, as well as against TB disease [4,5]. However, the pro-
tective efﬁcacy of BCG varies widely [6–10]. Despite advances in
immunology, there are no sufﬁciently validated immune corre-
lates of BCG-induced protection [11] and mechanisms of protection
are poorly understood. Accurate information is lacking on risk fac-
tors and immunological markers associated with subsequent TB
infection or disease among children from developing countries.
Proposed explanations for variation in BCG efﬁcacy include
population genetics [10,12], BCG vaccine strains [13–15], environ-
mental mycobacteria exposure [8,14,16], strains of Mycobacterium
http://dx.doi.org/10.1016/j.vaccine.2014.12.015
0264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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tuberculosis (M.tb) [17], exposure to chronic helminth infections
[9,12,18] and nutritional status [10,12].
BCG induces strong interferon gamma  (IFN-) production, a type
1 immune response essential for protection against M.tb [19,20].
IFN- alone may  not be sufﬁcient for disease prevention [20], but
excessive production of type 2 cytokines may  be detrimental [21].
Interleukin-10 (IL-10) is associated with suppression of protective
responses [22]. Although BCG induces only minor type 2 responses,
these may  be sufﬁcient in some individuals to undermine the efﬁ-
cacy of type 1-mediated immunity and cause immune-pathology
[23]. Differences predetermined in utero, or during the ﬁrst months
of life, may  explain the variable protection induced by BCG [8].
In this cohort of children who received BCG at birth, we inves-
tigated factors associated with LTBI at age ﬁve, factors associated
with cytokine responses to BCG at age ﬁve and whether cytokine
responses at one year were associated with subsequent LTBI.
Understanding these relationships may  aid the development of
new vaccines against tuberculosis, several of which are either
recombinant forms of BCG or designed to boost responses primed
by BCG [24].
2. Methods
2.1. Study design and setting
We  analysed data from the Entebbe Mother and Baby Study
(EMaBS), a randomised double-blinded placebo-controlled trial of
anthelminthic treatment in pregnancy and early childhood, con-
ducted in a peri-urban and rural setting by Lake Victoria, Uganda
(ISRCTN32849447). EMaBS was established to investigate effects of
helminths and their treatment on immune responses to vaccines
and on susceptibility to infectious and allergy-related diseases.
The design and results of the trial have been reported [25–27].
Brieﬂy, women attending antenatal care at Entebbe hospital were
enrolled between April 2003 and November 2005, and randomised
to receive single dose albendazole (400 mg)  or placebo and praz-
iquantel (40 mg/kg) or placebo in a 2 × 2 factorial design. At age
ﬁfteen months, their children were randomised to receive alben-
dazole or placebo quarterly until age ﬁve years. In 2008, additional
funding was awarded which allowed us to assess children for LTBI
at age ﬁve.
2.2. Study objectives
For this analysis, our primary objectives were to investigate (1)
factors associated with LTBI at age ﬁve years, (2) factors associated
with cytokine response to BCG at age ﬁve years, and (3) whether
cytokine responses at one year of age were associated with acqui-
sition of LTBI by age ﬁve years, among children with documented
BCG immunisation in infancy.
2.3. Study procedures
Socio-demographic data, blood and stool samples were obtained
at enrolment during pregnancy. Children received routine BCG
immunisation (with polio immunisation) at birth. The three BCG
vaccine strains used were provided by the National Medical Stores
according to availability: BCG-Russia (BCG-I Moscow strain, Serum
Institute of India, India); BCG-Bulgaria (BCG-SL 222 Soﬁa strain,
BB-NCIPD Ltd., Bulgaria); and BCG-Danish (BCG-SSI 1331, Statens
Seruminstitut, Denmark) [13]. Participants were seen at the clinic
for annual visits (at which they gave blood and stool samples and
were weighed and measured) and when ill.
Maternal history of TB exposure and disease was  ascertained
during pregnancy. History of TB exposure and disease in the child
was ascertained at annual visits and through illness visits. At one
and ﬁve years of age, cytokine responses to Mycobacterium tuber-
culosis crude culture ﬁltrate protein (M.tb-cCFP) were assessed.
LTBI at age ﬁve was  assessed using the Interferon gamma release
assay (IGRA), T-SPOT.TB® (Oxford Immunotec, Abingdon, UK), for
all children in the cohort who  turned age ﬁve from March 2009
onwards (when the TB sub-study began). Z-scores for weight-
for-age, height-for-age and weight-for-height at age ﬁve were
calculated from World Health Organisation (WHO) growth stan-
dards, using WHO  Anthro and AnthroPlus macros.
The trial was approved by the Science and Ethics Committee of
the Uganda Virus Research Institute, Uganda National Council for
Science and Technology, and London School of Hygiene and Tropical
Medicine. During pregnancy, women gave written, informed con-
sent for their and their child’s participation. The mother, father or
guardian gave written informed consent for additional procedures
in this study.
2.4. Immunological assays
Cytokine responses were assessed among children who  had doc-
umented BCG immunisation in infancy and who provided a blood
sample at ﬁve years of age, using a whole blood assay [12,18].
Brieﬂy, unseparated heparinised blood was diluted to a ﬁnal con-
centration of one-in-four (RPMI supplemented with penicillin,
streptomycin and glutamine), plated in 96-well plates and stimu-
lated with M.tb-cCFP (10 g/ml; kindly provided by John Belisle,
University of Colorado, Fort Collins, USA), tetanus toxoid (TT)
(12 Lf/ml; Statens Seruminstitut, Denmark), phytohaemagglutinin
(10 g/ml; Sigma, UK), or left unstimulated. Supernatants were
harvested on day six and frozen at −80 ◦C until analysed. Super-
natant cytokine concentrations were measured by Enzyme Linked
Immunosorbent Assay (ELISA) (Becton Dickinson, UK). Cytokine
production in unstimulated wells was subtracted from concentra-
tions produced in response to stimulation. Cytokine responses were
regarded as positive if greater than the higher of the mean plus two
standard deviations of the negative control for all assays and the
lowest standard in the assay (IFN- > 73 pg/ml; IL-5 > 34 pg/ml; IL-
13 > 18 pg/ml; IL-10 > 48 pg/ml at one year [18] and IFN- >9 pg/ml;
IL-5 > 8 pg/ml; IL-13 > 16 pg/ml; IL-10 > 8 pg/ml at ﬁve years). Val-
ues below the cut-off were set to zero.
Age of infection with cytomegalovirus (CMV) and her-
pes simplex virus (HSV) were determined by examining for
Immunoglobulin G responses by ELISA (DiaSorin, Saluggia, Italy).
To avoid confounding of secular trends with assay performance
variability, assays were performed in a randomised sequence after
completion of sample collection.
2.5. Parasitology and haematology
Stool was  examined for helminth ova and Strongyloides larvae
using Kato-Katz [28] and charcoal culture [27] methods, respec-
tively. Blood was  examined for Mansonella perstans using modiﬁed
Knott’s method [29] and for malaria by thick blood ﬁlm and Leish-
man’s stain. HIV status was  determined in mothers and children
≥18 months by rapid antibody test algorithm, and in younger chil-
dren by polymerase chain reaction [27].
2.6. Statistical methods
Data were double-entered into Microsoft Access (Redmond,
WA,  USA) and analysed using Stata v11 (College Station, TX, USA).
The sample size was  determined for the trial objectives; from the
planned enrolment of 2500 women we expected to retain 1046
children in follow-up at age ﬁve [25]. Assuming standard deviation
of 0.8log10 this sample size would give 80% power to detect a
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Fig. 1. Conceptual framework.
difference in mean cytokine response of 0.14log10 for an exposure
with prevalence 50%, at 5% signiﬁcance level.
Outcomes for this analysis were LTBI at age ﬁve years deter-
mined by T-SPOT.TB® result, and cytokine responses (IFN-, IL-5,
IL-13 and IL-10) to M.tb-cCFP at age ﬁve. Variables considered
as exposures were maternal and childhood anthelminthic treat-
ment, maternal socio-demographic characteristics and helminth
infections at enrolment; child sex, birth weight, HIV status, illness
history, TB exposure/disease, childhood helminth infections, and
anthropometry at age ﬁve; BCG vaccine strain used for immunisa-
tion. In addition, T-SPOT.TB® status was considered as an exposure
for age ﬁve cytokine responses.
Analyses followed a hierarchical causal diagram approach
(Fig. 1) [30]: factors at the same level were considered as potential
confounders for each other and for proximal factors. Crude associ-
ations were examined and a 15% signiﬁcance level used to decide
which factors to consider in multivariable analyses. Anthropome-
try variables were not included together in multivariable models
to avoid collinearity. Unadjusted effects of trial interventions are
reported.
Logistic regression was used to examine associations with LTBI
at age ﬁve. Cytokine responses were transformed to log10 (con-
centration + 1) and then analysed using linear regression with
bootstrapping to estimate bias corrected accelerated conﬁdence
intervals [31]; results were back-transformed to give geometric
mean ratios.
Spearman’s correlation coefﬁcients between cytokines
responses at one and ﬁve years were calculated. Logistic regression
was used to investigate whether cytokine responses at one year
were associated with LTBI at ﬁve years, restricting to children
with history of TB exposure or disease (which implies exposure)
between one and ﬁve years.
3. Results
We  enrolled 2507 women  resulting in 2345 live births, with
1474 children seen at age ﬁve years. Full details on participant
enrolment and follow-up are described elsewhere [13,18,26,27].
Of the 1474 children seen at age ﬁve, 1191 had documented BCG
immunisation in infancy, and cytokine responses to mycobacte-
rial antigen at age ﬁve were assessed among this group. For these
children, mean maternal age at enrolment was 24 years, 805 (68%)
were born to women  who  were urban residents at enrolment. Ten
percent of women  reported having been exposed to TB. Hook-
worm was the most prevalent helminth at 42%; 10% of mothers
had asymptomatic malaria. Of the children, 606 (51%) were female;
22 (1.9%) were HIV-infected; 638 (54%) had received BCG-Russia,
445 (37%) BCG-Bulgaria and 107 (9%) BCG-Danish. At age ﬁve, mean
(SD) weight-for-age, height-for-age and weight-for-height z-scores
were −0.9 (0.9), −1.3 (1.2) and −0.1 (1.2), respectively; 63 (5.5%)
had asymptomatic malaria, 639 (80.5%) and 691 (98.0%) children
had been infected with HSV or CMV, respectively, and 142 (5.9%)
had a history of tuberculosis exposure and, or, disease (12 had
probable TB disease, as reported by a parent).
At age ﬁve, T-SPOT.TB® results were available from 886 children
who reached age ﬁve years after the TB sub-study began, with 75
infected with tuberculosis (prevalence 8.5%, 95% CI: 6.7–10.5). Of
the 1191 children with cytokine results, 1024 (86.0%), 575 (48.3%),
1067 (89.7%) and 849 (71.3%) had detectable IFN-, IL-5, IL-10 and
IL-13 responses to M.tb-cCFP.
3.1. Factors associated with LTBI at age ﬁve years
Table 1 shows associations between each exposure and LTBI.
Rural residence was associated with reduced odds of LTBI, while
history of TB contact or disease was associated with increased odds
of LTBI. The odds of LTBI increased with the closeness of the TB
contact: compared to contact outside the household, ORs (95% CI)
of LTBI for children sharing a living room, a bedroom, and a bed
with the contact, were 0.54 (0.13–2.36), 1.79 (0.27–11.86) and 8.33
(1.33–52.03), respectively (trend p-value =0.02). There was no evi-
dence for association with LTBI for any other exposure.
3.2. Factors associated with cytokine response at age ﬁve years
There was moderate positive correlation between cytokine
responses at age one and ﬁve years for IFN-, IL-5 and IL-13
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Table  1
Factors associated with T-SPOT. TB among ﬁve year old children vaccinated with BCG in infancy.
Factora TB  infection  Crude  OR  (95%  CI)  P  Adjusted  OR  (95%  CI)b,c P
Positive  (%)  Negative  (%)
Socio-demographic  characteristics
Maternal  age  at  enrolment  1.02  (0.98–1.06)  0.27
Parity 1.11  (0.99–1.26)  0.08  1.10  (0.95–1.27)  0.21
Maternal education
None/primary  34  (7.4)  425  (92.6)  1
Secondary/tertiary  41  (9.7)  384  (90.4)  1.33  (0.83–2.15)  0.23
Household SES  0.92  (0.76–1.12)  0.41
Household crowding  1.14  (0.96–1.36)  0.14  1.03  (0.83–1.27)  0.80
Location of  residence
Urban  59  (10.5)  505  (89.5)  1  1
Rural 16  (5.1)  300  (94.9)  0.46  (0.26–0.81)  0.01  0.39  (0.19–0.78)  0.01
Maternal characteristics
Schistosoma  mansoni
No  58  (8.3)  645  (91.8)  1
Yes 17  (9.6)  161  (90.5)  1.17  (0.67–2.07)  0.58
Hookworm
No 45  (8.6)  478  (91.4)  1
Yes 30  (8.4)  328  (91.6)  0.97  (0.60–1.57)  0.91
Mansonella perstans
No  59  (8.4)  644  (91.6)  1
Yes 16  (8.7)  167  (91.3)  1.05  (0.59–1.86)  0.88
Malaria
No 70  (8.9)  717  (91.1)  1
Yes 4  (4.8)  79  (95.2)  0.52  (0.18–1.46)  0.21
Maternal TB  exposure
No  65  (8.2)  723  (91.8)  1
Yes 9  (9.8)  83  (90.2)  1.21  (0.58–2.51)  0.62
Maternal BCG  scar
No 27  (7.5)  332  (92.5)  1
Yes 46  (9.3)  449  (90.7)  1.26  (0.77–2.07)  0.36
Child characteristics
Sex
Male  30  (7.9)  350  (92.1)  1
Female 36  (9.9)  328  (90.1)  1.28  (0.77–2.13)  0.34
Birth weight  1.03  (0.59–1.82)  0.91
HIV status
Unexposed  64  (8.0)  737  (92.0)  1
Exposed-uninfected  9  (12.9)  61  (87.1)  1.70  (0.81–3.58)
Infected 2  (15.4)  11  (84.6)  2.09  (0.45–9.65)  0.30
BCG scar
No  29  (8.6)  307  (91.4)  1
Yes 41  (9.5)  391  (90.5)  1.11  (0.67–1.83)  0.68
BCG vaccine  strain
Russia  53  (10.1)  471  (89.9)  1  1
Bulgaria 13  (5.2)  237  (94.8)  0.49  (0.26–0.91)  0.73  (0.35–1.51)
Danish 6  (6.7)  84  (93.3)  0.63  (0.26–1.52)  0.05  2.25  (0.82–6.22)  0.17
History of  TB  contact/disease
No  60  (7.5)  740  (92.5)  1  1
Yes 15  (17.4)  71  (82.6)  2.61  (1.41–4.82)  <0.01  2.16  (1.02–4.55)  0.04
Any helminth  infection  ≤5  years
No 63  (8.8)  652  (91.2)  1
Yes 12  (7.0)  159  (93.0)  0.78  (0.41–1.48)  0.45
WHZ score,  age  5  0.95  (0.77–1.18)  0.67
HAZ score,  age  5  1.19  (0.96–1.49)  0.11  1.10  (0.86–1.40)  0.44
WAZ score,  age  5  1.15  (0.86–1.53)  0.36
Asymptomatic malaria,  age  5
No  73  (8.9)  752  (91.1)  1
Yes 1  (2.9)  34  (97.1)  0.30  (0.04–2.25)  0.24
Number of  malaria  events  0.96  (0.86–1.07)  0.46
Number of  diarrhoea  events  1.03  (0.96–1.12)  0.40
Number of  LRTI  events  1.12  (0.92–1.36)  0.26
Age of  infection  with  CMV  0.73  (0.43–1.23)  0.23
Age of  infection  with  HSV  1.19  (0.91–1.55)  0.22
Trial interventions
Maternal  albendazole  treatment
No  39  (8.8)  406  (91.2)  1
Yes 36  (8.2)  405  (91.8)  0.93  (0.57–1.49)  0.75
Maternal praziquantel  treatment
No  35  (7.6)  426  (92.4)  1
Yes 40  (9.4)  385  (90.6)  1.26  (0.79–2.03)  0.33
Childhood albendazole  treatment
No  37  (8.2)  414  (91.8)  1
Yes 38  (8.8)  395  (91.2)  1.08  (0.67–1.73)  0.76
a Missing values: maternal education 2; household socioeconomic status 16; crowding 2; location of residence 6; Schistosoma mansoni 5; hookworm 5; maternal malaria
16;  maternal TB contact 6; maternal BCG scar 36; birth weight 146; HIV status 2; child’s BCG scar 118; BCG strain 2; WHZ  score 104; HAZ score 111; WAZ  score 101;
asymptomatic malaria at ﬁve years 6; illness episodes 2.
b Adjusted for each other and for technician.
c Adjusted ORs for which 95% CIs exclude 1 are highlighted in bold.
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Table  2
Crude associations with cytokine response to crude culture ﬁltrate proteins of Mycobacterium tuberculosis in ﬁve year olds who  received BCG immunisation at birth.
Factor1 IFN- IL-5 IL-13 IL-10
Geometric
mean2
Crude GMR
(95%CI)3
Geometric
mean2
Crude GMR
(95%CI)3
Geometric
mean2
Crude GMR
(95%CI)3
Geometric
mean2
Crude GMR
(95%CI)3
Socio-demographic characteristics
Maternal age at enrolment 1.00 (0.98–1.03) 1.02 (1.00–1.04) 1.01 (0.99–1.04) 1.01 (0.99–1.02)
Parity  0.98 (0.90–1.05) 1.03 (0.97–1.09) 1.00 (0.93–1.07) 0.98 (0.93–1.03)
Maternal education
None/primary 169.0 1 5.7 1 25.7 1 50.7 1
Secondary/tertiary 163.3 0.97 (0.74–1.29) 5.7 0.99 (0.79–1.24) 25.5 0.99 (0.76–1.28) 50.6 1.00 (0.84–1.21)
Household SES 0.99 (0.90–1.12) 0.94 (0.86–1.03) 0.97 (0.87–1.07) 0.97 (0.90–1.05)
Household crowding 1.05 (0.94–1.16) 1.03 (0.94–1.12) 1.06 (0.95–1.17) 1.03 (0.95–1.10)
Location of residence
Urban 197.7 1 6.3 1 29.2 1 51.6 1
Rural 114.3 0.58 (0.42–0.76) 4.7 0.75 (0.60–0.95) 19.4 0.66 (0.50–0.87) 48.0 0.93 (0.75–1.11)
Maternal characteristics
Schistosoma mansoni
No 171.2 1 5.7 1 25.5 1 51.0 1
Yes  146.4 0.86 (0.58–1.20) 5.9 1.03 (0.97–1.09) 26.9 1.06 (0.77–1.44) 48.7 0.95 (0.73–1.18)
Hookworm
No  159.2 1 5.9 1 25.8 1 48.9 1
Yes  176.7 1.11 (0.84–1.46) 5.6 0.96 (0.77–1.21) 25.6 0.99 (0.78–1.29) 53.1 1.09 (0.89–1.30)
Mansonella perstans
No 174.4 1 6.2 1 26.8 1 52.3 1
Yes  143.1 0.82 (0.57–1.12) 4.6 0.74 (0.58–0.95) 22.4 0.83 (0.62–1.16) 43.9 0.84 (0.66–1.04)
Malaria
No  171.5 1 5.8 1 26.1 1 50.7 1
Yes  119.1 0.69 (0.42–1.06) 5.7 0.98 (0.67–1.41) 23.4 0.90 (0.56–1.39) 49.9 0.98 (0.72–1.29)
Maternal TB exposure
No 162.3 1 5.6 1 25.2 1 51.3 1
Yes  200.2 1.23 (0.77–1.86) 7.3 1.30 (0.89–1.89) 29.7 1.18 (0.77–1.78) 44.7 0.87 (0.64–1.18)
Maternal BCG scar
No 153.8 1 6.0 1 24.0 1 42.8 1
Yes  177.8 1.16 (0.88–1.53) 5.7 0.95 (0.75–1.21) 27.6 1.15 (0.86–1.49) 55.9 1.31 (1.06–1.61)
Child  characteristics
Sex
Male 151.4 1 5.6 1 26.0 1 52.1 1
Female 184.9 1.22 (0.92–1.61) 5.9 1.07 (0.86–1.32) 25.6 0.98 (0.75–1.27) 49.0 0.94 (0.78–1.14)
Birth  weight 1.25 (0.92–1.63) 1.29 (1.00–1.63) 1.15 (0.85–1.56) 0.95 (0.77–1.18)
HIV  status
Unexposed 170.6 1 5.8 1 25.8 1 50.3 1
Exposed, uninfected 250.9 1.47 (0.92–2.16) 6.9 1.19 (0.84–1.86) 41.1 1.59 (1.09–2.27) 49.5 0.98 (0.67–1.31)
Infected 10.9 0.06 (0.03–0.22) 2.0 0.34 (0.22–0.76) 2.3 0.09 (0.05–0.26) 65.5 1.30 (0.65-2.25)
BCG  scar
No 170.6 1 5.3 1 23.2 1 59.3 1
Yes  183.3 1.07 (0.79–1.44) 6.5 1.21 (0.96–1.55) 30.0 1.29 (1.01–1.72) 46.9 0.79 (0.65–0.97)
BCG  vaccine strain
Russia 266.9 1 6.6 1 34.9 1 52.0 1
Bulgaria 122.6 0.46 (0.35–0.60) 5.5 0.84 (0.66–1.07) 22.6 0.65 (0.51–0.85) 63.2 1.22 (1.01–1.46)
Danish 36.2 0.14 (0.08–0.23) 3.3 0.50 (0.36–0.76) 7.3 0.21 (0.13–0.34) 16.8 0.32 (0.32–0.48)
History of TB contact/disease
No 168.7 1 5.7 1 25.6 1 51.3 1
Yes  147.9 0.88 (0.48–1.43) 6.2 1.08 (0.71–1.60) 28.5 1.12 (0.70–1.76) 43.0 0.84 (0.58–1.17)
Any  helminth infection ≤5 years
No 179.3 1 5.7 1 26.0 1 52.3 1
Yes  122.6 0.68 (0.45–0.96) 6.0 1.06 (0.82–1.43) 25.1 0.96 (0.69–1.36) 43.7 0.84 (0.64–1.09)
WHZ  score, age 5 0.84 (0.75–0.95) 0.97 (0.87–1.07) 0.88 (0.78–0.98) 0.86 (0.80–0.93)
HAZ  score, age 5 1.37 (1.20–1.54) 1.21 (1.10–1.34) 1.28 (1.14–1.43) 1.24 (1.14–1.34)
WAZ  score, age 5 1.17 (1.00–1.39) 1.20 (1.05–1.36) 1.14 (0.97–1.33) 1.08 (0.96–1.20)
Asymptomatic malaria, age 5
No 174.3 1 6.0 1 26.1 1 49.3 1
Yes  82.2 0.47 (0.23–0.82) 3.8 0.63 (0.41–1.03) 21.1 0.81 (0.45–1.37) 66.9 1.36 (0.84–1.94)
Number of malaria events up to age 5 0.95 (0.89–1.01) 1.01 (0.96–1.06) 1.00 (0.95–1.05) 1.03 (1.00–1.07)
Number of diarrhea events up to age 5 1.00 (0.95–1.04) 1.03 (0.99–1.07) 1.02 (0.98–1.07) 1.02 (0.99–1.06)
Number of LRTI events up to age 5 1.02 (0.88–1.15) 1.03 (0.92–1.15) 1.01 (0.88–1.15) 1.02 (0.92–1.11)
Age  of infection with CMV  1.17 (0.95–1.37) 1.17 (1.00–1.38) 1.17 (0.97–1.37) 1.09 (0.96–1.20)
Age  of infection with HSV 0.99 (0.84–1.13) 0.94 (0.84–1.05) 1.00 (0.87–1.14) 1.00 (0.90–1.10)
T-spot TB
Negative 140.0 1 4.8 1 18.8 1 40.2 1
Positive 380.3 2.72 (1.51–4.35) 9.4 1.97 (1.14–3.41) 48.7 2.59 (1.46–4.14) 43.7 1.09 (0.70–1.62)
Trial  interventions
Maternal albendazole treatment
No 153.8 1 5.7 1 25.8 1 50.2 1
Yes  180.6 1.17 (0.89–1.54) 5.8 1.03 (0.82–1.28) 25.8 1.00 (0.79–1.32) 50.9 1.01 (0.83–1.19)
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Table  2 (Continued)
Factor1 IFN- IL-5 IL-13 IL-10
Geometric
mean2
Crude GMR
(95%CI)3
Geometric
mean2
Crude GMR
(95%CI)3
Geometric
mean2
Crude GMR
(95%CI)3
Geometric
mean2
Crude GMR
(95%CI)3
Maternal praziquantel treatment
No 171.3 1 5.7 1 26.2 1 49.3 1
Yes  162.2 0.95 (0.72–1.23) 5.8 1.01 (0.79–1.22) 25.4 0.97 (0.75–1.26) 51.9 1.05 (0.87–1.25)
Childhood albendazole treatment
No 194.8 1 6.2 1 30.5 1 50.6 1
Yes  141.3 0.73 (0.55–0.98) 5.3 0.86 (0.68–1.05) 21.6 0.71 (0.56–0.93) 50.5 1.00 (0.83–1.20)
1 Missing values: maternal education 3; household socioeconomic status 22; crowding 4; location of residence 9; Schistosoma mansoni 2; hookworm 2; Mansonella perstans
2;  maternal malaria 19; maternal TB contact 6; maternal BCG scar 10; birth weight 180; HIV status 3; child’s BCG scar 157; WHZ  score 158; HAZ score 163; WAZ  score 155;
asymptomatic malaria at ﬁve years 36; illness episodes 3.
2 Geometric mean of response concentration + 1.
3 GMR  = geometric mean ratio, conﬁdence intervals not including one are highlighted in bold.
(coefﬁcients 0.20, 0.20 and 0.26, respectively; p < 0.001), but no
correlation between IL-10 responses (coefﬁcient 0.00, p = 0.95).
Crude associations between exposures and cytokine response
at age ﬁve are shown in Table 2 and exposures remaining
associated after multivariable analysis in Table 3. HIV-infected
children showed lower IFN- and IL-13 responses, compared
to HIV-unexposed infants. Asymptomatic malaria at age ﬁve
was associated with reduced IFN- production. There were
no consistent associations with maternal helminths or with
maternal anthelminthic treatment. In multivariable analyses,
childhood helminth infection at any annual visit was  not asso-
ciated with cytokine responses, however, quarterly albendazole
treatment during childhood was associated with reduced IFN-
 and IL-13 responses to M.tb-cCFP. Maternal BCG scar was
associated with higher IL-10 response to M.tb-cCFP. Greater
height-for age was associated with increased responses for all
cytokines.
Vaccination with BCG-Danish was associated with lower
responses to M.tb-cCFP for all cytokines and BCG-Bulgaria with
lower IFN- and IL-13 responses, compared to BCG-Russia. IFN-
responses had waned between age one and ﬁve years for chil-
dren who  received BCG-Bulgaria or BCG-Danish, but had remained
similar for children who  received BCG-Russia (Fig. 2). For the
type 2 cytokines, responses among children who received BCG-
Russia or BCG-Bulgaria increased between one and ﬁve years, while
among children who received BCG-Danish they had stayed the
same (IL-5) or waned (IL-13).Responses to IL-10 had decreased sub-
stantially among children receiving BCG-Bulgaria or BCG-Danish,
with a smaller reduction seen among children receiving BCG-Russia
(Fig. 2).
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Fig. 2. Distribution of cytokine responses to Mycobacterium tuberculosis crude culture ﬁltrate protein at age one and ﬁve years, by BCG vaccine strain received in infancy.
Graphs show distributions of cytokine responses (panel A: IFN-, panel B: IL-5, panel C: IL-13, panel D: IL-10) to Mycobacterium tuberculosis crude culture ﬁltrate protein at
age  one year (indicated in blue) and age ﬁve years (indicated in pink), separately for children who  received BCG-Russia, BCG-Bulgaria and BCG-Danish-values for comparison
of  responses at age one with responses at age ﬁve for each BCG strain and cytokine, were calculated using Wilcoxon signed rank test. (For interpretation of the references to
color  in this ﬁgure legend, the reader is referred to the web version of this article.)
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Table  3
Factors associated with the cytokine response to crude culture ﬁltrate proteins of
Mycobacterium tuberculosis in ﬁve year olds who  received BCG immunisation at
birth, after adjustment for potential confounders.
Cytokine/Factor Adjusted GMR  (95% CI)a
Interferon-
Child’s HIV status
Unexposed 1
Exposed, uninfected 1.43 (0.88–2.17)
Infected 0.16 (0.05–0.51)
BCG vaccine strain
Russia 1
Bulgaria 0.46 (0.33–0.63)
Danish 0.19 (0.10–0.36)
Height-for-age z-score,
age 5 years
1.21 (1.04–1.41)
Asymptomatic malaria,
age 5 years
No 1
Yes 0.50 (0.22–0.96)
T-spot TB
Negative 1
Positive 2.05 (1.08–3.41)
Childhood albendazole
treatment
No 1
Yes 0.73 (0.55–0.98)
Interleukin-5
BCG vaccine strain
Russia 1
Bulgaria 0.89 (0.68–1.15)
Danish 0.59 (0.40–0.91)
Height-for-age z-score,
age 5 years
1.15 (1.03–1.29)
Interleukin-13
Child’s HIV status
Unexposed 1
Exposed, uninfected 1.58 (1.03–2.32)
Infected 0.13 (0.06–0.55)
BCG vaccine strain
Russia 1
Bulgaria 0.66 (0.50–0.89)
Danish 0.24 (0.15–0.41)
Height-for-age z-score,
age 5 years
1.14 (1.01–1.27)
T-spot TB
Negative 1
Positive 2.10 (1.17–3.63)
Childhood albendazole
treatment
No 1
Yes 0.71 (0.56–0.93)
Interleukin-10
Maternal BCG scar
No 1
Yes 1.24 (1.01–1.56)
BCG vaccine strain
Russia 1
Bulgaria 1.27 (1.01–1.58)
Danish 0.45 (0.28–0.73)
Height-for-age z-score,
age 5 years
1.22 (1.11–1.32)
a Figures are geometric mean ratios of cytokine production, with bootstrap 95%
conﬁdence intervals.
Positive T-SPOT.TB® at age ﬁve years was associated with higher
IFN- and IL-13 response to M.tb-cCFP.
Among 58 children with a history of TB contact who had
cytokine and T-SPOT.TB® data available, there was no evidence
of association between cytokine responses to M.tb-cCFP at one
year and odds of LTBI at ﬁve years of age (Table 4). We also
found no evidence of a relationship between child’s BCG scar
and T-SPOT.TB® in this subgroup (OR = 1.08, 95% CI: 0.34-3.42,
p = 0.89).
Table 4
Associations between cytokine responses to mycobacterial antigens at age one and
odds of subsequent infection with M.  tuberculosis infection by ﬁve years of age,
among 58 children with a history of tuberculosis exposure.
Cytokine response
to cCFP at age 1
Crude odds ratio P Adjusted odds ratioa P
IFN- 1.10 (0.58–2.09) 0.76 1.14 (0.55–2.37) 0.72
IL-5  1.56 (0.80–3.05) 0.20 1.88 (0.90–3.93) 0.09
IL-13 1.45 (0.72–2.94) 0.28 1.73 (0.76–3.96) 0.19
IL-10 1.23 (0.48–3.16) 0.65 1.21 (0.45–3.26) 0.71
a Adjusted for zone of residence.
4. Discussion
In this study, using data from a large birth cohort in Entebbe,
Uganda, only urban location of residence and history of TB contact
or disease during childhood were associated with LTBI at ﬁve years.
Children testing positive for LTBI at ﬁve years had increased type
1 and type 2 cytokine responses to mycobacterial antigens. Other
determinants for cytokine response at ﬁve years were HIV infection,
anthropometry, malaria infection, quarterly albendazole treatment
during childhood, maternal BCG scar and the BCG vaccine strain
used to immunise the child during infancy.
LTBI prevalence among Ugandan children aged ﬁve years was
9% using T-SPOT.TB®, comparable with the 12% prevalence among
children from Tanzania assessed by QuantiFERON(R)-TB assay
[32] but less than the 21% prevalence reported among Ethiopian
children [33]. Urban location of residence and history of TB con-
tact/disease were positively associated with LTBI, with odds of
LTBI increasing with the closeness of the TB contact. In contrast
to ﬁndings from Ethiopia, we did not ﬁnd that helminth expo-
sure, either prenatally, or in childhood, was associated with LTBI
[33].
In the same cohort, we  have previously investigated factors
associated with cytokine responses to M.tb-cCFP at age one [13,18].
Consistent with these ﬁndings, HIV infection remained associated
with large reductions in IFN- and IL-13 responses at age ﬁve, and
concurrent asymptomatic malaria infection remained associated
with reduced IFN- response. These results emphasise the impor-
tance of HIV infection as a suppressor of immune responses. Since
there were no consistent patterns for HIV-exposed-uninfected chil-
dren, it appears that exposure to HIV in utero has no long-term
impact on subsequent immune response, as long as the child
remains uninfected (despite short-term differences observed in
other studies [34,35]).
Anthropometry measures were consistently associated with
higher cytokine responses, and these associations were stronger
than those observed at one year, indicating that poor growth may
have increasing importance among older children.
Consistent with our ﬁndings at one year [18], maternal helminth
infections were not associated with cytokine responses at age
ﬁve, suggesting that contrary to some hypotheses [36], maternal
helminth infection during pregnancy does not explain poor BCG
efﬁcacy in the tropics.
As at one year, maternal BCG scar was  associated with cytokine
responses at age ﬁve, although the association pattern had
changed: maternal BCG scar was associated with reduced Th2
cytokine responses at age one, but increased IL-10 responses at age
ﬁve. These ﬁndings support the idea that some aspect of maternal
exposure, or of maternal immune response, to mycobacteria may
inﬂuence the infant immune response to mycobacterial antigen.
Cohort children were randomised to quarterly albendazole or
placebo between 15 months and ﬁve years. Those receiving alben-
dazole had reduced IFN- and IL-13 responses compared to those
receiving placebo, as previously reported [26]. This is unlikely to
be due to worm removal since childhood helminth infection was
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not associated with increased cytokine responses (in crude anal-
yses, it was associated with reduced responses). These may  be
chance ﬁndings, since no effects were observed on the response to
other antigens tested [26] and given the large number of statistical
tests undertaken. Indeed, we did not formally adjust for multiplic-
ity, but instead focus on patterns and consistency of results, when
discussing our ﬁndings.
At ﬁve years, BCG vaccine strain was associated with cytokine
production, with children who received BCG-Danish showing con-
sistently reduced responses compared to children who  received
BCG-Russia, and children who received BCG-Bulgaria showing
reduced type 1 and 2 responses, but increased regulatory (IL-10)
responses. This implies that the choice of BCG vaccine has a direct
effect on the immune response elicited, a hypothesis that is also
supported by ﬁndings from other studies which have examined
the association between BCG strain and immune response dur-
ing infancy [37,38]. Differences in vaccines are due to evolution
from the original BCG vaccine [14,39], for example BCG-Bulgaria is
genetically derived from BCG-Russia. “Early” BCG vaccines, such as
BCG-Russia, have been hypothesised to have better efﬁcacy than
later vaccines [39], although we saw little evidence for this in rela-
tion to LTBI, and a recent systematic review found little evidence
of a relationship between BCG strain and subsequent efﬁcacy [40].
These ﬁndings contrast with those we reported at one year,
where infants who received BCG-Danish had markedly higher
responses [13]. One possible explanation is that BCG-Danish, ini-
tially more immunogenic, could protect against TB infection and
possibly against other non-TB mycobacteria, thus children immu-
nised with BCG-Danish are now less likely to have acquired the
infections that are the strongest inducers of responses at ﬁve
years. However, we found no evidence that LTBI status mod-
iﬁed the association between BCG vaccine strain and cytokine
response to support this hypothesis. Second, studies have shown
that the magnitude of cytokine response to mycobacterial anti-
gen gradually reduces over time [3,41]. We  found that the decline
in cytokine response varied with BCG vaccine strain, with IFN-
and IL-10 responses among children who received BCG-Danish or
BCG-Bulgaria waning faster than among children who  received
BCG-Russia. Type 2 responses increased among children who
received BCG-Russia or BCG-Bulgaria, but stayed the same or
decreased among children who received BCG-Danish.
We  found no evidence that immune response to mycobacterial
antigen at one year was associated with subsequent LTBI, among
those with documented exposure to TB disease, although power for
this analysis was limited due to the relatively low LTBI prevalence.
Further follow-up of the cohort is planned to investigate this. It
remains a priority to identify reliable bio-markers of protection fol-
lowing immunisation, if we are to develop a better vaccine against
TB.
Our study population exhibited high-prevalence, low-intensity
helminth burden in mothers, but low prevalence in children, pre-
sumably related to mass drug administration and urbanisation.
Findings might differ in populations with continuing high helminth
prevalence and in non-TB endemic areas.
In conclusion, prenatal exposure to maternal helminth and
malaria infections are unlikely to explain poor BCG vaccine efﬁ-
cacy in the tropics. Concurrent HIV or malaria infection and poor
growth are important predictors of immune response. Policies
aimed at prevention of mother-to-child HIV transmission and poor
growth may  contribute to effective immunisation programmes
in the tropics. Only urban location of residence and having a
history of TB contact/disease were associated with LTBI at ﬁve
years in this cohort, and it remains to be seen whether the fac-
tors we have identiﬁed as important for cytokine responses at
one and ﬁve years will be associated with TB infection at a later
age.
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